GlassScriptPhysician profile
Michelle Tiffany Wright
NPI 1649924309
$2,083.21
in general payments reported to CMS, 2019-2025
18 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $311 · 2023: $659 · 2024: $987 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481 · Travel and Lodging: $206 · Debt Forgiveness: $85.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,480.59 |
| Travel and Lodging | $206.48 |
| Debt Forgiveness | $85.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $783.91 | 2024 | Linq II |
| Novo Nordisk INC | $235.63 | 2022-2023 | |
| Amgen INC. | $147.12 | 2023 | Repatha, Otezla |
| Edwards Lifesciences Corporation | $126.77 | 2025 | Evoque |
| Genzyme Corporation | $117.14 | 2024 | |
| Organon LLC | $115.68 | 2022 | |
| Lilly USA, LLC | $106.15 | 2023 | Mounjaro |
| Baxter Healthcare | $85.48 | 2024 | |
| Merck Sharp & Dohme LLC | $84.08 | 2023 | Belsomra, Steglatro, Verquvo |
| Glaxosmithkline, LLC. | $75.87 | 2022-2023 | Shingrix, Bexsero, Arexvy |
| Pfizer INC. | $58.46 | 2023 | |
| Abbvie INC. | $36.52 | 2023 | |
| Idorsia Pharmaceuticals US INC | $27.39 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $20.56 | 2023 | Auvelity |
| Sumitomo Pharma America, INC. | $17.44 | 2023 | Gemtesa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $16.72 | 2023 | Azstarys |
| Currax Pharmaceuticals LLC | $14.93 | 2023 | Contrave |
| Abbott Laboratories | $13.36 | 2023 | Freestyle Libre 2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.